Biopharmaceuticals market, estimated at USD 186 billions in 2017 and projected to reach USD 526 billions by 2025 with a CAGR of 13.8%. Among different product segments, monoclonal antibodies (mAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US $51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US $56.3 billion, and further expected reach a projected US $144.5 billion by 2020.

The broad therapeutic applications of biopharmaceuticals commercialized so far are for some types of cancer, arthritis, diabetes (treated by insulin), blood diseases and anemia (treated by erythropoietin), and hemophilia (treated by blood clotting factors).Indus Gene is planning to produce insulin (Over the next 20 years, the WHO predicts that worldwide insulin sales will grow from $12 B to $54 B) and erythropoietin (world market of $6 B). The Company has the advantage of having senior scientists with wide exposure to US biotech industry.